Cure8 research brief
Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness, and possible anti-inflammatory mechanisms relevant to IBD care.
Adults with IBD and obesity, gastroenterologists/IBD clinicians, obesity specialists, and researchers of IBD–metabolic interactions.
The review compiles existing studies but does not present new trial data. Findings suggest GLP-1RAs can produce meaningful weight loss and improve systemic inflammation markers in some studies, but gastrointestinal side effects are common and may limit use. Endoscopic disease activity data are scarce, and results on fecal calprotectin are inconsistent.
The authors call for longitudinal studies to determine long-term clinical and endoscopic impacts.
Structured content depth: abstract — the curator note is grounded in the source-provided abstract and does not reflect review of full studies. The reviewed studies are heterogeneous with limited endoscopic outcome data; longer-term and prospective studies were recommended by the authors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...
